Category: Psychedelic Bulletin - Page 3 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control; A Look at the Latest Oregon Psilocybin Services Complaints

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control; A Look at the Latest Oregon Psilocybin Services Complaints

Post published:November 1, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question

Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question

Post published:October 25, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist

Post published:October 18, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

Post published:October 11, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Post published:October 4, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Post published:September 27, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Post published:September 20, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Post published:September 9, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Post published:August 30, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Post published:August 15, 2024
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.